Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of AV-006 in Healthy Subjects
NCT03931876Phase 1Unknown
- Sponsor
- Arixa Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avibactam tomilopil in Gram-negative bacterial infection, sponsored by Arixa Pharmaceuticals. Primary endpoint: Incidence of treatment related adverse events, vital signs data, ECGs, clinical laboratory tests at 7 days. Status: unknown.
02
Drugs
avibactam tomilopil
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT03931876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931876.